Paclitaxel in Veterinary Oncology: Formulation and Regulatory-History Profile

paclitaxel is covered as taxane antineoplastic agents; hazardous antineoplastic medicine, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.

Taxane antineoplastic agents; hazardous antineoplastic medicine. Paclitaxel.

Paclitaxel.

Paclitaxel stabilises microtubules and prevents their normal disassembly, arresting dividing cells during mitosis. Vehicle and formulation are clinically inseparable from the active molecule because conventional polyethoxylated castor-oil formulations can provoke severe hypersensitivity in dogs.

Veterinary studies have evaluated micellar, nanoparticulate and newer oral formulations in dogs with selected malignancies. A formulation-specific result cannot be transferred to conventional paclitaxel or to another taxane.

Veterinary studies have evaluated micellar, nanoparticulate and newer oral formulations in dogs with selected malignancies. A formulation-specific result cannot be transferred to conventional paclitaxel or to another taxane.

Formulation-dependent clinic treatment; conventional intravenous vehicles can be unsafe in dogs

A multicentre randomized canine trial evaluated a water-soluble micellar formulation in nonresectable mast-cell tumours. More recent early-phase work evaluated oral paclitaxel with a transporter inhibitor. These studies show clinical investigation, not universal equivalence or a current broadly authorised veterinary product.

Related class overview: Taxane chemotherapy, formulation, infusion and evidence. This page remains the drug-specific profile; the linked page explains the broader class.

Myelosuppression, gastrointestinal effects and formulation-related hypersensitivity are central. Infusion reactions can be acute and serious; oral combinations add their own interaction and absorption issues.

Premedication, infusion equipment, formulation excipients and transporter inhibitors are protocol-specific. Substituting a human formulation or another paclitaxel product can materially change safety and exposure.

The EMA Paccal Vet marketing-authorisation application was withdrawn in 2012 after the committee could not conclude a positive benefit-risk balance. It must not be described as an authorised current EU veterinary product. This Directory page does not establish a current FDA-approved canine paclitaxel cancer product.

Veterinary availability and lawful extra-label use vary. Historical or investigational formulations are not proof of current commercial authorisation.

A specialist verifies the exact formulation, evidence for the tumour, venous or oral plan, premedication and emergency readiness. Baseline and follow-up blood counts and organ assessment are protocol-specific. Breathing change, collapse, infusion-site pain, fever or severe gastrointestinal signs require urgent review.